Molecular polymorphism of Aβ in Alzheimer's disease
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease is defined pathologically by the presence of senile plaques, which consist primarily of extracellular aggregates of fibrillar Abeta peptide, and neurofibrillary tangles, which are abnormal, intracellular bundles of fibrillar tau protein. The advent of amyloid binding agents as diagnostic imaging probes for Alzheimer's disease (AD) has made it imperative to understand at a molecular and disease level what these ligands are reporting. In addition to improving the accuracy of diagnosis, we argue that these selective ligands can serve as probes for molecular polymorphisms that may govern the pathogenicity of abnormal protein aggregates.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Self-Propagating, Molecular-Level Polymorphism in Alzheimer's ß-Amyloid Fibrils
Petkova, A. T., Leapman, R. D., Guo, Z., Yau, W.-M., Mattson, M. P., & Tycko, R. (2005) · Science · doi:10.1126/science.1105850 · Cited by 1,687
Neuropathology of older persons without cognitive impairment from two community-based studies
Bennett, D. A., Schneider, J. A., Arvanitakis, Z., Kelly, J. F., Aggarwal, N. T., Shah, R. C., & Wilson, R. S. (2006) · Neurology · doi:10.1212/01.wnl.0000219668.47116.e6 · Cited by 1,336 · cited 2×
“Strain differences might also account for the fact that some cognitively normal humans have large amounts of cerebral Aβ [4], and for other features of the disorder such as inflammation and cerebral β-amyloid angiopathy (CAA) [3,56].”
Exogenous Induction of Cerebral ß-Amyloidogenesis Is Governed by Agent and Host
Meyer-Luehmann, M., Coomaraswamy, J., Bolmont, T., Kaeser, S., Schaefer, C., Kilger, E., Neuenschwander, A., Abramowski, D., Frey, P., Jaton, A. L., et al. (2006) · Science · doi:10.1126/science.1131864 · Cited by 971 · cited 1×
“In vivo, heterogeneous Aβ [3,51] deposits suggestive of Aβ strains have been induced by different exogenous Aβ seeds in APPtransgenic mice [35].”
Self-citationPost-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease
Ikonomovic, M. D., Klunk, W. E., Abrahamson, E. E., Mathis, C. A., Price, J. C., Tsopelas, N. D., Lopresti, B. J., Ziolko, S., Bi, W., Paljug, W. R., et al. (2008) · Brain · doi:10.1093/brain/awn016 · Cited by 933
Kayed, R., Head, E., Sarsoza, F., Saing, T., Cotman, C. W., Necula, M., Margol, L., Wu, J., Breydo, L., Thompson, J. L., et al. (2007) · Molecular Neurodegeneration · doi:10.1186/1750-1326-2-18 · Cited by 773
Wilcock, G. K., & Esiri, M. M. (1982) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(82)90155-1 · Cited by 608
Crystal, H., Dickson, D., Fuld, P., Masur, D., Scott, R., Mehler, M., Masdeu, J., Kawas, C., Aronson, M., & Wolfson, L. (1988) · Neurology · doi:10.1212/wnl.38.11.1682 · Cited by 586
Neocortical Neurofibrillary Tangles Correlate With Dementia Severity in Alzheimer's Disease
Bierer, L. M., Hof, P. R., Purohit, D. P., Carlin, L., Schmeidler, J., Davis, K. L., & Perl, D. P. (1995) · Archives of Neurology · doi:10.1001/archneur.1995.00540250089017 · Cited by 514 · cited 4×
“Their utility as biomarkers, though, is hampered by the weak correlation of the amount and regional distribution of Aβ deposition with the extent of neurodegeneration that results in functional deficits [5,8,50].”
InfluentialImaging of amyloid burden and distribution in cerebral amyloid angiopathy
Johnson, K. A., Gregas, M., Becker, J. A., Kinnecom, C., Salat, D. H., Moran, E. K., Smith, E. E., Rosand, J., Rentz, D. M., Klunk, W. E., et al. (2007) · Annals of Neurology · doi:10.1002/ana.21164 · Cited by 495 · cited 1×
“CAA, which is found to varying degrees in most AD subjects, also binds PIB [15].”
Monoclonal antibodies that target pathological assemblies of Aβ
Lambert, M. P., Velasco, P. T., Chang, L., Viola, K. L., Fernandez, S., Lacor, P. N., Khuon, D., Gong, Y., Bigio, E. H., Shaw, P., et al. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04157.x · Cited by 314 · cited 2×
“Some of the antioligomer antibodies may indeed recognize conformational variants, notably the A11, I11 and OC (officer) antibodies [17,26,55].”
Research works printed but not linked: 41
- Aguzzi, 2007, Insights into prion strains and neurotoxicity, Nat. Rev. Mol. Cell. Biol., 8, 552, 10.1038/nrm2204 · DOI · Paper page
- Aslund, 2007, Studies of luminescent conjugated polythiophene derivatives: enhanced spectral discrimination of protein conformational states, Bioconjug. Chem., 18, 1860, 10.1021/bc700180g · doi:10.1021/bc700180g
- Attems, 2004, Amyloid beta peptide 1–42 highly correlates with capillary cerebral amyloid angiopathy and Alzheimer disease pathology, Acta Neuropathol. (Berl.), 107, 283, 10.1007/s00401-004-0822-6 · DOI
- Chandra, 2006, Design, synthesis, and structure-activity relationship of novel thiophene derivatives for beta-amyloid plaque imaging, Bioorg. Med. Chem. Lett., 16, 1350, 10.1016/j.bmcl.2005.11.055 · DOI
- Collinge, 2007, A general model of prion strains and their pathogenicity, Science, 318, 930, 10.1126/science.1138718 · DOI · Paper page
- Fodero-Tavoletti, 2007, In vitro characterization of Pittsburgh compound-B binding to Lewy bodies, J. Neurosci., 27, 10365, 10.1523/JNEUROSCI.0630-07.2007 · DOI · Paper page
- Forsberg, A., Engler, H., Almkvist, O., Blomquist, G., Hagman, G.,Wall, A., Ringheim, A., Langstrom, B., Nordberg, A., 2007. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol. Aging, doi:10.1016/j.neurobiolaging.2007.03.029, in press. · DOI · Paper page
- Hardy, 2002, The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics, Science, 297, 353, 10.1126/science.1072994 · DOI · Paper page
- Ikeda, 1989, Morphology and distribution of plaque and related deposits in the brains of Alzheimer's disease and control cases. An immunohistochemical study using amyloid beta-protein antibody, Lab. Invest., 60, 113
- Kalback, 2002, APP transgenic mice Tg2576 accumulate Abeta peptides that are distinct from the chemically modified and insoluble peptides deposited in Alzheimer's disease senile plaques, Biochemistry, 41, 922, 10.1021/bi015685+ · DOI · Paper page
- Kayed, 2006, Conformation-dependent anti-amyloid oligomer antibodies, Methods Enzymol., 413, 326, 10.1016/S0076-6879(06)13017-7 · DOI · Paper page
- Kemppainen, 2007, PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment, Neurology, 68, 1603, 10.1212/01.wnl.0000260969.94695.56 · DOI · Paper page
- Klunk, 2004, Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B, Ann. Neurol., 55, 306, 10.1002/ana.20009 · DOI · Paper page
- Klunk, 2004, Amyloid deposits in transgenic PS1/APP mice do not bind the amyloid PET tracer, PIB, in the same manner as human brain amyloid, Neurobiol. Aging, 25, 232, 10.1016/S0197-4580(04)80779-6 · doi:10.1016/s0197-4580(04)80779-6
- Klunk, 2003, The binding of 2-(4′-methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component, J. Neurosci., 23, 2086, 10.1523/JNEUROSCI.23-06-02086.2003 · DOI · Paper page
- Kung, M.P., Hou., C., Zhuang, Z.P., Cross, A.J., Maier, D.L., Kung, H.F., 2004. Characterization of IMPY as a potential imaging agent for beta-amyloid plaques in double transgenic PSAPP mice. Eur. J. Nucl. Med. Mol. Imag. (10.1007/S00259-004-1487-z). · DOI
- Kung, 2002, IMPY: an improved thioflavin-T derivative for in vivo labeling of beta-amyloid plaques, Brain Res., 956, 202, 10.1016/S0006-8993(02)03436-4 · DOI · Paper page
- Kuo, 2001, Comparative analysis of amyloid-beta chemical structure and amyloid plaque morphology of transgenic mouse and Alzheimer's disease brains, J. Biol. Chem., 276, 12991, 10.1074/jbc.M007859200 · DOI · Paper page
- LeVine, 2003, Y10W beta(1–40) fluorescence reflects epitope exposure in conformers of Alzheimer's beta-peptide, Arch. Biochem. Biophys., 417, 112, 10.1016/S0003-9861(03)00322-9 · DOI
- LeVine, 2005, Multiple ligand binding sites on A beta(l–40) fibrils, Amyloid, 12, 5, 10.1080/13506120500032295 · DOI · Paper page
- LeVine, 2006, Chapter 11. Models of Alzheimer's disease, 121
- Lim, 2006, Solid-state NMR structural studies of the fibril form of a mutant mouse prion peptide PrP89-143(P101L), Solid State Nucl. Magn. Reson., 29, 183, 10.1016/j.ssnmr.2005.09.017 · doi:10.1016/j.ssnmr.2005.09.017
- Matsunaga, 2002, A pH-dependent conformational transition of Abeta peptide and physicochemical properties of the conformers in the glial cell, Biochem. J., 361, 547, 10.1042/bj3610547 · doi:10.1042/bj3610547
- Miller, 2003, Humoral immune response to fibrillar beta-amyloid peptide, Biochemistry, 42, 11682, 10.1021/bi030100s · DOI
- Murphy, 2007, Aβ solubility and deposition during AD progression and in APPXPS1 Knock-in mice, Neurobiol. Dis., 10.1016/j.nbd.2007.06.002 · DOI
- Nilsson, 2007, Imaging distinct conformational states of amyloid-beta fibrils in Alzheimer's disease using novel luminescent probes, ACS Chem. Biol., 2, 553, 10.1021/cb700116u · DOI · Paper page
- O’Nuallain, 2002, Conformational antibodies recognizing a generic amyloid fibril epitope, Proc. Natl. Acad. Sci. U.S.A., 99, 1485, 10.1073/pnas.022662599 · DOI · Paper page
- Petkova, 2006, Experimental constraints on quaternary structure in Alzheimer's beta-amyloid fibrils, Biochemistry, 45, 498, 10.1021/bi051952q · DOI · Paper page
- Rabinovici, 2007, 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration, Neurology, 68, 1205, 10.1212/01.wnl.0000259035.98480.ed · DOI · Paper page
- Somerville, 1999, Host and transmissible spongiform encephalopathy agent strain control glycosylation of PrP, J. Gen. Virol., 80, 1865, 10.1099/0022-1317-80-7-1865 · DOI
- Tagliavini, 1988, Preamyloid deposits in the cerebral cortex of patients with Alzheimer's disease and nondemented individuals, Neurosci. Lett., 93, 191, 10.1016/0304-3940(88)90080-8 · DOI · Paper page
- Toyama, 2007, The structural basis of yeast prion strain variants, Nature, 449, 233, 10.1038/nature06108 · DOI · Paper page
- Walker, 2006, Koch's postulates and infectious proteins, Acta Neuropathol., 112, 1, 10.1007/s00401-006-0072-x · DOI
- Weissmann, 2004, The state of the prion, Nat. Rev. Microbiol., 2, 861, 10.1038/nrmicro1025 · DOI · Paper page
- Wetzel, 2007, Plasticity of amyloid fibrils, Biochemistry, 46, 1, 10.1021/bi0620959 · DOI
- Wisniewski, 1989, Spectrum of morphological appearance of amyloid deposits in Alzheimer's disease, Acta Neuropathol. (Berl.), 78, 337, 10.1007/BF00688170 · DOI · Paper page
- Yagi, 2007, Visualization and classification of amyloid beta supramolecular assemblies, Biochemistry, 46, 15009, 10.1021/bi701842n · DOI
- Yamaguchi, 1988, A variety of cerebral amyloid deposits in the brains of the Alzheimer-type dementia demonstrated by beta protein immunostaining, Acta Neuropathol., 76, 541, 10.1007/BF00689591 · DOI · Paper page
- Ye, 2005, Delineation of PET imaging agent binding sites on beta -amyloid peptide fibrils, J. Biol. Chem., 280, 23599, 10.1074/jbc.M501285200 · DOI · Paper page
- Yoshiike, 2007, Pore-forming proteins share structural and functional homology with amyloid oligomers, Neuromol. Med., 9, 270, 10.1007/s12017-007-0003-6 · DOI
- Zhang-Nunes, 2006, The cerebral beta-amyloid angiopathies: hereditary and sporadic, Brain Pathol., 16, 30, 10.1111/j.1750-3639.2006.tb00559.x · DOI · Paper page
Cited by
The Amyloid State of Proteins in Human Diseases
Eisenberg, D., & Jucker, M. (2012) · Cell · doi:10.1016/j.cell.2012.02.022 · Cited by 1,744
Self-propagation of pathogenic protein aggregates in neurodegenerative diseases
Jucker, M., & Walker, L. C. (2013) · Nature · doi:10.1038/nature12481 · Cited by 1,663
Self-citationAmyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging
Rowe, C. C., Ellis, K. A., Rimajova, M., Bourgeat, P., Pike, K. E., Jones, G., Fripp, J., Tochon-Danguy, H., Morandeau, L., O'Keefe, G., et al. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.007 · Cited by 986
Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders
Jucker, M., & Walker, L. C. (2011) · Annals of Neurology · doi:10.1002/ana.22615 · Cited by 622
“The differential seeding ability of synthetic vs. natural A β aggregates (which may contain additional factors) suggests the possibility that A β , like prions, can misfold into polymorphic and polyfunctional strains 51, 59-62 .”
Self-citationJucker, M. (2010) · Nature Medicine · doi:10.1038/nm.2224 · Cited by 401
Metadata
- Authors
- LeVine, H., & Walker, L. C.
- Venue
- Neurobiology of Aging
- Publisher
- Elsevier BV
- Published
- 2010-04
- Volume
- 31
- Issue
- 4
- Pages
- 542-548
- ISSN
- 0197-4580 (ISSN-L)
- OpenAlex
- W2015234786
- Cited by
- 52
- References
- 14
- FWCI
- 2.01
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Molecular polymorphism of Aβ in Alzheimer's disease. https://app.cochat.ai/papers/10.1016/j.neurobiolaging.2008.05.026
- The paper
- LeVine, H., & Walker, L. C. (2010). Molecular polymorphism of Aβ in Alzheimer's disease. Neurobiology of Aging. https://doi.org/10.1016/j.neurobiolaging.2008.05.026
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.